





















Ej coloproctol (rio j). 2 0 1 4;3  4(3):131–135
Journal  of
Coloproctology
www.jco l .org .br
riginal article
he epidemiological  proﬁle  of  inﬂammatory  bowel
isease patients  on biologic  therapy  at a  public
ospital in  Alagoas
etrille André Cavalcante de Barrosa, Alberson Maylson Ramos da Silvaa,
.Á.d.F. Lins Netob,∗
Universidade Federal de Alagoas (UFAL), Maceió, AL, Brazil
Coloproctology Service, Hospital Universitário Professor Alberto Antunes (HUPAA), Universidade Federal de Alagoas (UFAL), Maceió,
L, Brazil
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 16 July 2013
ccepted  15 May 2014







a  b  s  t  r  a  c  t
Introduction: Inﬂammatory Bowel Diseases (IBD), represented by Crohn’s disease (CD) and
ulcerative  colitis (UC) are chronic and idiopathic inﬂammatory conditions involving the gas-
trointestinal tract. There are several epidemiological studies that have shown an increased
incidence  of IBD worldwide.
Objective:  To analyze the epidemiological proﬁle of patients with IBD under biologic ther-
apy,  treated in a coloproctology outpatient clinic, Hospital Universitario Professor Alberto
Antunes,  Alagoas.
Methods:  Retrospective observational clinical study, conducted by collecting patients’
records  and interviewing them at the time of follow-up.
Results: 40 patients were evaluated: 70% female, 27 patients (67.5%) with CD and 13 (32.5%)
with  UC, mean age of 37.8 years and predominance of white ethnicity. The ileocolonic area
was  more frequently affected among patients with CD (33.3%), whereas the extensive colitis
presentation  predominated among UC patients (61.5%). 95% of the patients received some
medication before using biologicals. 70% of the respondents remain in deep remission in
the  period of 6–60 months.
Conclusion:  The socioeconomic proﬁle of patients was similar to that described in the lit-
erature.  Crohn’s disease was more frequent in our study, while extensive colitis was  more
common  among UC patients. Most patients used biologicals after failure of other treatment
options.dade Brasileira de Coloproctologia. Published by Elsevier Editora Ltda. ©  2014 Socie∗ Corresponding author.
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Perﬁl  epidemiológico  dos  pacientes  portadores  de  Doenc¸a  Inﬂamatória
Intestinal,  que  fazem  uso  da  terapia  biológica,  atendidos  em  um  hospital
da  rede  pública  de  Alagoas
Palavras-chave:
Doenc¸a  intestinal inﬂamatória
Perﬁl  epidemiológico
Colite ulcerativa
Doenc¸a  de Crohn
Medicamentos biológicos
r  e  s  u  m  o
Introduc¸ão: As Doenc¸as  Inﬂamatórias Intestinais (DII), representadas pela Doenc¸a  de Crohn
(CD) e Retocolite Ulcerativa Inespecíﬁca (RCUI), são condic¸ões  inﬂamatórias crônicas,
idiopáticas, que envolvem o trato gastrointestinal. Vários são os estudos epidemiológicos
que  vêm demonstrando o aumento na incidência da DII em todo o mundo.
Objetivo:  Analisar o perﬁl epidemiológico dos pacientes portadores de DII, que fazem uso
da terapia biológica, atendidos no Servic¸o  de Coloproctologia do Hospital Universitário Pro-
fessor Alberto Antunes da Universidade Federal de Alagoas.
Métodos: Estudo clínico descritivo observacional transversal, realizado através da coleta
dos prontuários dos pacientes e entrevista com os mesmos no momento da consulta de
acompanhamento.
Resultados: Foram avaliados 40 pacientes, sendo 28 do gênero feminino e 12 do gênero
masculino. 27 pacientes (67,5%) apresentavam DC e 13 (32,5%) apresentavam RCUI, com
uma média de idade de 37,8 anos com predominância da etnia branca. A região íleo-colônica
foi a localizac¸ão  mais frequente entre os pacientes com DC (33,3%), enquanto que a colite
extensiva predominou entre os portadores de RCUI (61,5%). 95% dos pacientes ﬁzeram uso
de algum medicamento antes do uso dos biológicos. 70% dos entrevistados permanecem
com remissão profunda no período de 6 a 60 meses.
Conclusão: O perﬁl socioeconômico dos pacientes foi semelhante ao descrito na literatura.
Doenc¸a  de Crohn foi mais freqüente em nosso estudo, enquanto que colite extensiva foi
a forma mais comum entre os portadores de RCUI. A maioria dos pacientes fez uso dos
biológicos após falha das outras opc¸ões  de tratamento clínico.
© 2014 Sociedade Brasileira de Coloproctologia. Publicado por Elsevier Editora Ltda.
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Inﬂammatory Bowel Disease (IBD), represented by Crohn’s
disease  (CD) and Ulcerative Colitis (UC), are chronic, idio-
pathic  inﬂammatory conditions, which probably involve an
immune reaction of the body against its own gastrointesti-
nal  tract.1,2 Considering that these are chronic conditions that
affect  preferably young people in the productive phase and
contribute  to long-term morbidity, thus causing changes in
the  social, psychological and professional realms, IBDs are
gaining  importance, constituting a public health problem in
many countries, with a large ﬁnancial impact on the health-
care  system.3–6
There are several epidemiological studies showing an
increased  incidence of IBD in the world.1–8 A recent epi-
demiological research estimates that about 4 million people
worldwide  have either UC or CD, with 1.4 million of these
cases  occurring in the United States.9 The male/female ratio
is  similar for both UC and CD, with women showing a slightly
higher  incidence. Both diseases are more  commonly diag-
nosed  in young adults. The vast majority of new diagnoses
are  detected in the age ranging between 15–40 years, with
the  peak incidence occurring early in the second decade of
life.2
Brazil is still considered an area of low prevalence of IBD,
despite  the signiﬁcant increase in the incidence of thesediseases  in reports of the national literature. In our envi-
ronment, these diseases are not considered of compulsory
notiﬁcation, which leads us to think that perhaps IBDs are
being  underdiagnosed.4
The management of IBD will depend on its severity and of
the  extent and anatomical region involved. A large number
of  drugs have been used, achieving remission, but not a cure
for  the disease. Among the classes used in conventional ther-
apy,  aminosalicylates, glucocorticoids, immunomodulators
and antibiotics are mentioned.10,11 However, the conventional
therapeutic options for IBD are limited, both by the inability
to  maintain clinical remission, and by their side effects.10 In
this  context, a new therapeutic approach emerges based on
the  use of antagonists of tumor necrosis factor  (TNF-): the
so-called  biological therapy.
The  evidence for use of biological therapy comes from
large-scale randomized clinical trials. The class of anti-TNF-
agents,  in general, has demonstrated considerable effec-
tiveness  in moderate to severe intraluminal CD.12 It is not
completely clear whether the biologic therapy approach would
be  most effective when used at an early stage, with possi-
ble  beneﬁcial impacts on the natural course of the disease,
or  would be indicated later, after a failure to respond to
13traditional drugs. Therefore, the lack of national epidemi-
ological data on IBD, in association with the currently existing
paradigm  regarding the early use of biological therapy in the















































Table 1 – Disease location according to the Montreal
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reatment of these diseases, corroborates the relevance of this
tudy.
bjective
o analyze the epidemiological proﬁle of patients with inﬂam-
atory  bowel disease using biological therapy treated at
he  Coloproctology Service, Hospital Universitário Professor
lberto  Antunes, with characterization of patients according
o  social, clinical and disease-related aspects.
ethod
his is an observational cross-sectional descriptive study that
as  conducted from March 2012 to March 2013 in the colo-
roctology outpatient clinic, Hospital Universitário Professor
lberto  Antunes (HUPAA), a reference service in colorectal dis-
ases’ care.
The  study population involved all patients with inﬂam-
atory bowel disease (IBD): Crohn’s disease, ulcerative colitis
r  indeterminate colitis, seen, registered and followed up in
he  coloproctology outpatient clinic, HUPAA, with a total of
4  patients. The sample consisted of forty (40) patients, in
iew  of the withdrawal or exclusion of some individuals in
he  population.
Patients of both genders, regardless of age, diagnosed with
BD,  seen at the coloproctology outpatient clinic, HUPAA –
FAL,  and currently in biological therapy were enrolled. On
he  other hand, patients who,  for some reason, had to stop
heir  biologic therapy, in addition to patients using biologicals
or  different pathologies of IBD, were excluded from the study.
The  medical records of the subjects were  acquired by con-
ultation  of HUPAA – UFAL ﬁles, under authorization by the
nstitution  proposing the study, with assurance of complete
onﬁdentiality in relation to personal data and clinical infor-
ation,  according to the standards proposed by the Resolution
NS/MS  196/96.
In  cases where information from medical records was
nsufﬁcient for implementation of the Research Protocol for
BD,  patients were  approached during routine consultations,
o  conduct an interview aimed at complementing this proto-
ol.
After  collecting the clinical records, the social aspects,
edical history and current history of the disease were ana-
yzed,  in order to adapt these data to the research objectives
by  inclusion and exclusion criteria) and to implement the
esearch  Protocol for Inﬂammatory Bowel Disease. In the
vent  that the information contained in medical records was
nsufﬁcient,  the Protocol was  complemented with interviews
ith  the patient itself.
After  data collection, the material was  scanned into a
atabase  and processed.
The  following project was  approved by the Ethics andesearch Committee, Centro de Ensino Superior de Maceió
CESMAC), and registered under protocol number 1419/12. All
atients interviewed were  informed about the study objectives
nd  signed two (2) copies of a Free and Informed Consent TermTerminal ileum 7 25.9
Upper gastrointestinal tract 2 7.5
– FICT. For those cases in which the analysis of medical records
was  done, FICT exemption was  requested.
Results
After conducting all methodological steps, with interviews
and  medical records’ analysis, a ﬁnal number of 40 patients
was  reached; of those, 12 (30%) were  male and 28 (70%) were
female  patients. The patients’ age ranged from seven to 67
years,  with a mean of 37.8 years (for male patients, the mean
was  35.6 years and for female patients, 38.8 years). Regarding
ethnicity: 22 (55%) were  white, 16 (40%) mixed race and 2 (5%)
were  black.
Regarding the patients’ diagnosis, it was observed that 27
(67.5%)  patients had CD, while 13 (32.5%) had UC.  This diagno-
sis  was  deﬁned before age 40 in 32 patients (80%) (2 patients
>16  years and 30 patients >20 years). Eight (20%) patients, of
more  than 40 years of age had their diagnosis conﬁrmed.
In  our study, 27 patients (67.5%) did not undergo any surgi-
cal  procedure related to their condition, but 13 (32.5%) patients
had  been submitted to some type of surgery.
Among the patients evaluated, it was  found that 38 (95%)
already  had undergone some type of drug therapy prior to the
use  of biologicals, whereas two (5%) were  on biological therapy
as  ﬁrst choice of treatment for IBD. Among the commonly used
alternative  therapies (aminosalicylates, antibiotics, cortico-
steroids  and immunosuppressive agents), 13 patients (34.2%)
had  made use of them all, followed by 10 individuals (26.3%)
who  had used three of these drugs and nine (23.7%) who  used
only  two of them. Four (10.5%) patients were on monotherapy
with  immunosuppressive agents, while two (5.3%) had used
only  aminosalicylates before the biologicals.
Regarding the social and family history, 22 (55%) patients
reported no smoking habit throughout life, while eight (20%)
had  been smokers and 10 (25%) did not answer. Familial recur-
rence  was  present in four (10%) patients, compared to 25
(62.5%)  individuals who did not have any relative with a diag-
nosis  for IBD and 11 (27.5%) patients who could not inform
about  the occurrence of these diseases in their families.
The  location of the disease was  diagnosed and established
by  means of upper gastrointestinal endoscopy, colonoscopy
and  CT (enterography) (Table 1).
Crohn’s disease manifested itself in a non-stenosing/non-
penetrating inﬂammatory presentation in 15 (55.5%), in a
stenotic  presentation in nine (33.3%) and in a penetrating pre-
sentation  in three (11.1%) subjects.
In patients with UC, the predominant location, according
to  the Montreal classiﬁcation, was  an extensive colitis in eight
cases  (61.5%), followed by left colitis in ﬁve cases (38.5%). In our
j). 2 0
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sample, no cases of ulcerative proctitis or proctosigmoiditis
were  found.
Extra-intestinal manifestations were present in 28 (70%)
patients.  It was  noted that these manifestations were more
frequently  found in patients with UC (76.9%) when compared
with  patients with CD (66.7%).
With respect to medication duration of use, 23 patients
(57.5%) use biological agents between 2 and 5 years and 17
(42.5%)  for less than two years. Thirty-three patients (82.5%)
showed  no adverse effects during the biological therapy,
whereas seven (17.5%) subjects had some type of reaction with
the  use of this medication (erythema, pain at the infusion site,
tuberculosis  in two patients, herpes simplex, acne).
Regarding the course of the clinical picture, it was  observed
that  28 (70%) patients achieved complete remission, while 12
(30%)  remained with symptoms.
Discussion
We  demonstrated in this study a predominance of female
gender  (70%) among patients with IBD, consistent with the
national  and international literature.1,2,4,14,15 Regarding the
age  of our patients, a distribution pattern similar to that
described in the literature was  observed, with a minimum of
seven  and a maximum of 67 years old, with a mean age cor-
responding  to the peak incidence among young adults (mean
age,  37.8 years).1–5,7,10,14,15 Regarding ethnicity, there was  pre-
dominance of white subjects (55%) when compared to other
races,  a fact that agrees with the epidemiology of IBD.1,2,7
Other factors associated with the etiology of IBD are famil-
ial  recurrence and smoking.2,7,16 The hereditary character
was  present in four patients (10%). However, it is notewor-
thy  that 11 patients (27.5%) were  not certain about relatives
possibly affected, which may  have contributed to an under-
estimation of this variable. Regarding smoking, eight patients
(20%)  reported that were  smokers at some point in their life.
However,  10 patients (25%) declined to answer this question,
underestimating, again, the statistical results of this variable.
According  to studies recently published,4–6,8,10,15 UC is the
most prevalent disease among IBDs – a ﬁnding that goes
against  the statistics of our study, where 67.5% of the par-
ticipants  were  CD patients. Most patients were diagnosed
between 17 and 39 years, agreeing with the literature, most
likely  because the peak incidence of IBD covers this age
group.1,2
With regard to the location of the disease, we observed
that in patients with CD, the most affected area in the diges-
tive  tract (ileocolonic area) corresponds to that found in
the  literature.2,4,5,10,15 As for its behavior, non-stenosing/non-
penetrating CD was  the more  prevalent presentation among
the  patients studied (55.5%), which is consistent with Souza
et  al.4 ﬁndings.
On the other hand, these studies reveal that ulcerative
proctitis is the most common clinical presentation among
patients  with UC. This goes against our study ﬁndings of
extensive  colitis as the more  prevalent presentation and
localization.2,4,5,10,15
According to some studies,6,12 the extra-intestinal mani-
festations are highly prevalent among patients with IBD. In our 1 4;3  4(3):131–135
study, we observed a prevalence of 70%, occurring more  often
in  patients with UC (76.9%) compared with patients with CD
(66.7%).  This latter ﬁnding is at odds with our ﬁndings, which
show  that such events are more  common in patients with CD.
Pharmacological treatment has been extensively
researched, aiming to decrease the symptoms and
inﬂammation.3,5,7,10,11 The early use of biologic therapy
was  not yet adopted; this option is reserved only for cases
of  moderate or severe bowel disease in patients refractory
to  conventional treatment.13 In the present study we  found
that  95% of the patients used another type of drug therapy
before  starting the use of biologicals, which speaks in favor of
the  referenced studies. Of these patients, 34.2% used all drug
classes  prescribed in the treatment of IBD, without clinical
improvement.
Regarding surgical treatment, 32.5% of the patients
required some form of surgical intervention during the course
of  the disease, all of them being patients with CD, which is sim-
ilar  to results in the literature that show a higher prevalence
of  surgical procedures among CD patients when compared to
UC.4,5
With respect to the use of biological therapy, most patients
evaluated (57.5%) made use of this medication for more  than
two  years. The remission of the disease was  obtained in
most  cases (70%), which is consistent with recently published
studies.10,14
Conclusion
Patient characteristics were  similar to those found in the lit-
erature,  with a predominance of women (70%), young adults
(mean  age, 37.8 years) and presence of CD (67.5%). In relation
to  this condition, the ileocolonic manifestation was  the most
frequent  presentation (33.3%), while extensive colitis or pan-
colitis  was  more  common among patients with UC (61.5%).
The  vast majority of patients (95%) made use of biologicals
as  late therapy and 70% progressed with remission of their
symptoms.
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